Two new measurements have been added to the Health Equity Report Card (HERC)—a tool for improving the quality and equity of cancer care. This expansion is part of ongoing efforts to address the impact of structural and interpersonal racism as a cause of disparities in cancer outcomes in the United States.
New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that breast cancer patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.
National Comprehensive Cancer Network publishes free NCCN Guidelines for Patients with information on improving well-being and reducing suffering and distress for people with cancer; available at NCCN.org/patientguidelines.
72% of the centers surveyed by NCCN continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin. Overall, 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.
Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader; launches new resources for a type of pediatric lymphoma.
NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.
New study in JNCCN from the University of Michigan found English speakers who call a hospital general information line were able to get information on next steps to access cancer care 94% of the time, compared to 38% for Spanish speakers and just 28% for Mandarin speakers.
The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on reducing gaps in patient care for people with limited-stage (LS) and extensive stage (ES) small cell lung cancer.
The National Comprehensive Cancer Network (NCCN)—a not-for-profit alliance of leading academic cancer centers—announces Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO), replacing the retiring longtime CEO, Robert W. Carlson, MD.
The National Comprehensive Cancer Network (NCCN) today announces the publication of NCCN Guidelines for Patients: Hodgkin Lymphoma in Children.
The National Comprehensive Cancer Network expands materials tailored for the MENA region to help improve patient outcomes by standardizing local cancer care; includes new adaptation focused on genetic/familial cancer risk, as well as care for ovarian/fallopian tube/primary peritoneal cancers.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.
The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
National Comprehensive Cancer Network’s Department of Policy and Advocacy calls on Federal Government, pharmaceutical industry, providers, and payers to work together on solutions, as 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin; two medications that are used in combination to cure many types of cancer.
United States-based NCCN representatives visit Hanoi, Vietnam to work with local experts to improve quality-of-life for patients with cancer throughout the country.
Katy Winckworth-Prejsnar, MPH, Senior Manager of Global Policy and Strategic Alliances for National Comprehensive Cancer Network (NCCN), to Co-Chair Non-Communicable Diseases Roundtable for the Global Health Council (GHC)
Theresa J. Franco, Fred & Pamela Buffett Cancer Center; F. Marc Stewart, City of Hope National Medical Center; Douglas E. Wood, UW Medicine Fred Hutchinson Cancer Center; and Donna Powell, NCCN, presented with awards during NCCN 2023 Annual Conference.
NCCN has published a new addition to its library of patient resources, expanding the information available for breast cancer. The new NCCN Guidelines for Patients: Inflammatory Breast Cancer joins patient and caregiver resources for Breast Cancer Screening and Diagnosis, Ductal Carcinoma In Situ, Invasive Breast Cancer, and Metastatic Breast Cancer.
The National Comprehensive Cancer Network (NCCN) and the NCCN Foundation announce four winners for the 2023 NCCN Foundation Young Investigator Awards. These annual awards honor up-and-coming leaders in oncology research working to investigate and advance cancer care.
The NCCN 2023 Annual Conference took place in-person in Orlando and virtually, with a particular focus on human connection. That connection was underscored with more than 2,000 registrants from across the continuum of cancer care, including approximately 1,000 who returned in-person for the first time since 2019. Educational sessions highlighted the importance of ensuring care meets the latest standards while also rejecting a one-size-fits-all approach.
The University of Chicago Medicine Comprehensive Cancer Center has been named as the newest member institution of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of leading cancer centers. There are now 33 academic centers across the United States contributing multidisciplinary subject matter experts to 61 different panels determining the latest evidence-based expert consensus recommendations for risk assessment, prevention, evaluation and treatment, surveillance, supportive care, and survivorship throughout the cancer care continuum.
The National Comprehensive Cancer Network (NCCN) announces the addition of the University of Chicago Medicine Comprehensive Cancer Center as the newest Member Institution to join the not-for-profit alliance of leading cancer centers.
NCCN 2023 Annual Conference featuring more than a thousand worldwide oncology professionals will present new research findings, latest NCCN Guidelines updates, and best practices for achieving quality cancer care delivery, in Orlando and online March 31—April 2, 2023. Visit NCCN.org/conference for more.
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announces a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI).
New research in the February 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network illustrates how the use of an algorithm to calculate a patient-reported symptom complexity score can help oncologists identify patients who are at increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care, and the reduction of healthcare costs.
An ongoing pilot project aims to evaluate the feasibility of implementing the Health Equity Report Card (HERC) as a tool for improving the quality and equity of cancer care and continues the Elevating Cancer Equity collaboration from the National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF)–highlighted on World Cancer Day.
National Comprehensive Cancer Network’s new Diversity, Equity, & Inclusion (DEI) Directors Forum is working together to improve diversity of clinical staff representation across nation’s leading academic cancer centers.
New research in JNCCN finds that immunotherapy from immune checkpoint (PD-1) inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
NCCN is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.
Annual NCCN Patient Advocacy Summit explores stories and data highlighting barriers to high-quality care that LGBTQ+ people with cancer experience, examining persistent setbacks and promising developments.
The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on improving patient care and outcomes in locally advanced or metastatic bladder cancer.
A study in JNCCN, led by researchers at Duke University School of Medicine, found that Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment for ovarian cancer compared to Non-Hispanic White patients, even after adjusting for healthcare access issues.
United States-based National Comprehensive Cancer Network enters strategic cooperation agreement with Chinese medical information website to publish and translate evidence-based expert consensus guidelines for cancer care; now available at nccnchina.org.cn.
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—has been named winner for the 2022 Excellence in Cancer Patient Education award from the Cancer Patient Education Network (CPEN).
New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.
On World Mental Health Day, NCCN announced an updated NCCN Distress Thermometer, is available in more than 70 languages, to help people around the world identify and address psychosocial stressors that may raise challenges when coping with having cancer, its symptoms, or treatment.
The 2022 NCCN Annual Congress on Hematologic Malignancies™ (#NCCNhem22) is taking place Friday, October 14–Saturday, October 15, 2022 in New York City. All live sessions will also stream remotely through a virtual event platform.
National Comprehensive Cancer Network Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis details clarified expert consensus to help guide providers on latest data and information, available at NCCN.org/covid-19.
The new patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN’s library of NCCN Guidelines for Patients®, published through funding from the NCCN Foundation® and available online free of charge.
New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery.
Gerontology researchers teamed up with hematologic-oncology investigators from Brigham and Women’s Hospital and the Dana-Farber Cancer Institute to look at the association between older patients with blood cancers who were taking multiple medications and their corresponding frailty. They also created a new scale based on a list of Potentially Inappropriate Medications (PIMs) from the NCCN Guidelines® for Older Adult Oncology—called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale—and found it to be more effective at predicting frailty than conventional methods.
Newly-published NCCN Guidelines for Pediatric Central Nervous System Cancers synthesize latest evidence to help care teams ensure children with high-grade gliomas have best possible outcomes; available free at NCCN.org.
New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.
The National Comprehensive Cancer Network (NCCN) convened an oncology policy summit in Washington D.C. on building a workplace that includes support for people with cancer and their caregivers. The program, which also featured a virtual attendance option, examined how workplace norms and expectations have changed in recent years, particularly since the onset of the COVID-19 pandemic.
National Comprehensive Cancer Network honors oncology leaders: Robert Winn, MD, and Shonta Chambers, MSW, named joint Partners in Cancer Care; William Gradishar, MD, named Rodger Winn Award recipient for work on NCCN Guidelines; Hema Sundar, PhD, named Employee of the Year.
A new study in JNCCN finds patients with cancer who smoke are more likely to receive evidence-based cessation assistance by using the ELEVATE program, increasing the likelihood of better outcomes.
National Comprehensive Cancer Network’s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care and biology, such as novel combination therapy, equitable access to cellular therapies, immune cell dysfunction, liquid biomarkers, genetic ancestry, oncogenic vulnerabilities, and MAIT cell antitumor activity.
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
International collaboration involving NCCN and Polish oncology officials publishes first of several evidence-based expert consensus guidelines with latest cancer treatment recommendations, adapted for regional needs, beginning with cervical cancer.